This study aims to evaluate the long-term cost-effectiveness of Degludec insulin liraglutide injection in adult type 2 diabetes mellitus patients with poor glycemic control, to inform health care and health policymakers, as well as provide evidence for hospital drug selection and rational clinical use. This evidence concerns the gene INS and diabetes mellitus.